| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 01/20/2004 | US6680372 Antibodies specific for growth differentiation factor-7 |
| 01/20/2004 | US6680296 Compositions comprising bouganin and a cell binding ligand are particularly useful to kill cells of a target population |
| 01/20/2004 | US6680198 Engraftable human neural stem cells |
| 01/20/2004 | US6680169 Poliovirus replicons encoding therapeutic agents and uses thereof |
| 01/20/2004 | US6680057 Using protein comprising partial amino acid sequence 2 or 10 |
| 01/20/2004 | US6680056 Stimulating proliferation of cytolytic t cells |
| 01/15/2004 | WO2004005551A1 Antisense modulation of nf-kappa-b p50 subunit expression |
| 01/15/2004 | WO2004005544A2 Marker genes for determining renal toxicity |
| 01/15/2004 | WO2004005529A2 GEF-H1b: BIOMARKERS, COMPLEXES, ASSAYS AND THERAPEUTIC USES THEREOF |
| 01/15/2004 | WO2004005512A1 Nove protein and use thereof |
| 01/15/2004 | WO2004005511A1 Tumor-lysing virus growing selectively in tumor cells |
| 01/15/2004 | WO2004005510A1 NOVEL Nogo RECEPTOR-LIKE POLYPEPTIDE AND DNA THEREOF |
| 01/15/2004 | WO2004005498A1 Chimeric gb virus b (gbv-b) |
| 01/15/2004 | WO2004005488A2 Replacing liver cells with bone marrow-derived cells for treating disease and expressing therapeutic genes |
| 01/15/2004 | WO2004005476A2 Nucleic acid compositions for stimulating immune responses |
| 01/15/2004 | WO2004005464A2 Compounds promoting delivery of genes |
| 01/15/2004 | WO2004005457A2 Tfc/ beta-catenin regulated genes for treating cancer |
| 01/15/2004 | WO2004005341A2 Full-length interferon gamma polypeptide variants |
| 01/15/2004 | WO2004004798A2 Central airway administration for systemic delivery of therapeutics |
| 01/15/2004 | WO2004004763A2 Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
| 01/15/2004 | WO2004004760A1 Vaccine for feline infectious peritonitis |
| 01/15/2004 | WO2004004758A1 Method to enhance an immune response of nucleic acid vaccination |
| 01/15/2004 | WO2004004663A2 Compositions and methods for ligament growth and repair |
| 01/15/2004 | WO2004004451A1 Methods of screening compounds for grk6 modulating activity |
| 01/15/2004 | WO2003080794A3 Inhibition of rna function by delivery of inhibitors to animal cells |
| 01/15/2004 | WO2003080648A3 Raav vector compositions and methods for the treatment of choroidal neovascularization |
| 01/15/2004 | WO2003078592A3 Method for the purification, production and formulation of oncolytic adenoviruses |
| 01/15/2004 | WO2003072126A3 Use of a fibroblast growth factor-binding protein for the treatment and diagnosis of diabetic wound healing problems |
| 01/15/2004 | WO2003070905A3 Electroporation methods for introducing bioactive agents into cells |
| 01/15/2004 | WO2003070895A3 RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 01/15/2004 | WO2003068936A3 Inhibition of lung metastases by aerosol delivery of p53 gene and anti-cancer compounds |
| 01/15/2004 | WO2003063786A3 Methods and composition for delivering nucleic acids and/or proteins to the respiratory system |
| 01/15/2004 | WO2003061587A3 USE OF TGF-β ANTAGONISTS TO TREAT OR TO PREVENT CHRONIC TRANSPLANT REJECTION |
| 01/15/2004 | WO2003057148A3 Use of biomolecular targets in the treatment and visualization of tumors |
| 01/15/2004 | WO2003052117A3 Methods and products related to non-viral transfection |
| 01/15/2004 | WO2003050271A3 In vitro production of dendritic cells from cd14+ monocytes |
| 01/15/2004 | WO2003023048A3 METHODS FOR DIAGNOSING AND TREATING DISEASES AND CONDITIONS ASSOCIATED WITH PROTEIN KINASE C$g(l) |
| 01/15/2004 | WO2003004620A3 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| 01/15/2004 | WO2002092854A3 Genes expressed in breast cancer as prognostic and therapeutic targets |
| 01/15/2004 | WO2002086093A3 Methods of using a hyaluronan receptor |
| 01/15/2004 | WO2002080888A3 Estrogen receptor-related receptor alpha (err) agonist for inducing cartilage formation |
| 01/15/2004 | WO2002078526A3 Cancer-testis antigens |
| 01/15/2004 | WO2002066629A9 Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates |
| 01/15/2004 | WO2002061037B1 Administration of nucleic acid sequence to female animal |
| 01/15/2004 | WO2002046364A8 Genes associated with mechanical stress, expression products therefrom, and uses thereof |
| 01/15/2004 | US20040010814 Comprises nucleotide sequences coding kinases for developing contraceptives and controlling sex determination in animals |
| 01/15/2004 | US20040010811 Mixture comprising modulator for cancer activity; anticarcinogenic agents; tumor diagnosis; immunotherapy |
| 01/15/2004 | US20040010134 Albumin fusion proteins |
| 01/15/2004 | US20040010132 53 human secreted proteins |
| 01/15/2004 | US20040010120 Novel polypeptides and nucleic acids encoding same |
| 01/15/2004 | US20040010118 Novel proteins and nucleic acids encoding same |
| 01/15/2004 | US20040009951 DNA deamination mediates innate immunity to (retro)viral infection |
| 01/15/2004 | US20040009949 Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids |
| 01/15/2004 | US20040009947 Compounds and methods for enhancing delivery of free polynucleotide |
| 01/15/2004 | US20040009942 Administering a polynucleotide having an immunostimulatory sequence comprising the sequence 5'-C, G-3'; a respiratory virus antigen is not administered |
| 01/15/2004 | US20040009941 Microspheres and adjuvants for DNA vaccine delivery |
| 01/15/2004 | US20040009940 Gene delivery formulations and methods for treatment of ischemic conditions |
| 01/15/2004 | US20040009939 Methods of enhancing immune induction involving MDA-7 |
| 01/15/2004 | US20040009937 Intranasal administration of an immunogenic composition of a microflora organism having an expression vector wherein said expression vector comprises a heterologous nucleic acid that encodes for an antigen. |
| 01/15/2004 | US20040009935 Antisense oligonucleotides, targeted to nucleic acids encoding p21-activated kinase 2, that inhibit the expression of the kinase |
| 01/15/2004 | US20040009921 Inhibiting the proliferation of a eukaryotic cell whose growth is stimulated by beta-catenin-mediated gene transcription by administering a non-endogenous source of RXR nuclear receptor protein, and an agonist of the protein |
| 01/15/2004 | US20040009900 Soluble molecular complex comprising an expressible gene encoding the secretory protein complexed with a carrier of a cell-specific binding agent and a gene-binding agent which releases the gene under intracellular conditions |
| 01/15/2004 | US20040009899 Treating dominant disorders |
| 01/15/2004 | US20040009897 Stabilized synthetic immunogen delivery system |
| 01/15/2004 | US20040009604 Plasmid which codes envelop fusogenic membrane protein for treating cell proliferative disorders; antitumor agents; immunotherapy; gene therapy |
| 01/15/2004 | US20040009603 Antiviral vectors |
| 01/15/2004 | US20040009588 Comprises targeted adenoviral expression vector coding antitumor agent; gene therapy; gene expression inhibition |
| 01/15/2004 | US20040009553 Comprises nucleotide sequences coding cardiolipin for diagnosis and treatment of lung, heart and respiratory disorders |
| 01/15/2004 | US20040009551 Comprises nucleotide sequences coding peptide antibiotic for treatment of parasitic infection and cell proliferative disorders |
| 01/15/2004 | US20040009535 Comprises immunoglobulin which inhibits homodimer formation associated with a transforming growth factor polypeptide, sclerostin (SOST), for treating osteopenia, osteoporosis and bone fractures |
| 01/15/2004 | US20040009505 A pair of genetic engineered primers for the mutagenic amplification, therapeutic treatment |
| 01/15/2004 | US20040009502 Identification and tissue distribution of two novel spliced variants of the mouse LATS2 gene |
| 01/15/2004 | US20040009480 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 01/15/2004 | US20040009478 Human nucleic acid sequences from prostate tumor tissue |
| 01/15/2004 | US20040009463 Method for PR-39 peptide mediated selective inhibition of IkappaBalpha |
| 01/15/2004 | US20040009191 Inactivated virulence genes |
| 01/15/2004 | US20040009171 Methods for the treatment of carcinoma |
| 01/15/2004 | US20040009163 HUMAN AMINOACYL-tRNA SYNTHETASE POLYPEPTIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS |
| 01/15/2004 | US20040009158 Administering endothelial progenitor cells comprising gene codes for proteins; prophylaxis of congenital protein defects or genetic disorders |
| 01/15/2004 | US20040009153 GP64-null baculoviruses pseudotyped with heterologous envelope proteins for gene therapy |
| 01/15/2004 | US20040009152 Materials and methods for prevention and treatment of RNA viral diseases |
| 01/15/2004 | US20040009151 Methods for delivering recombinant adeno-associated virus virions to the liver of a mammal |
| 01/15/2004 | US20040009147 Administering mixtures of antibodies and tumor necrosis factors, immunosuppressants, antibiotics, antiinflammatory agents, cytokines, angiogenesis inhibitors or fibroblast growth factors; prophylaxis of graft versus host disease |
| 01/15/2004 | US20040008336 Method and system of determining chamber seasoning condition by optical emission |
| 01/15/2004 | CA2494508A1 Nucleic acid compositions for stimulating immune responses |
| 01/15/2004 | CA2493860A1 Marker genes for determining renal toxicity |
| 01/15/2004 | CA2491947A1 The use of specified tcf target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which tcf/.beta.-catenin/wnt signalling plays a central role |
| 01/15/2004 | CA2491907A1 Oncolytic virus replicating selectively in tumor cells |
| 01/15/2004 | CA2491513A1 Compositions and methods for ligament growth and repair |
| 01/15/2004 | CA2491321A1 Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
| 01/15/2004 | CA2491286A1 Methods of screening compounds for grk6 modulating activity |
| 01/15/2004 | CA2491178A1 Full-length interferon gamma polypeptide variants |
| 01/15/2004 | CA2491129A1 Central airway administration for systemic delivery of therapeutics |
| 01/14/2004 | EP1380651A2 Recombinant fowlpox virus with intact FPV-tk-gene |
| 01/14/2004 | EP1380650A1 Conditionally replicating viral vectors and their use |
| 01/14/2004 | EP1380644A1 The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role |
| 01/14/2004 | EP1380594A1 Fibroblast growth factor-10 |
| 01/14/2004 | EP1380593A1 Soluble rage protein |
| 01/14/2004 | EP1379873A2 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| 01/14/2004 | EP1379695A2 New polynucleotides and polypeptides of the ifnalpha-21 gene |